Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score
Morgane Bouquot, MD1,7, Anthony Dohan, MD, PhD2,7, Etienne Gayat, MD, PhD3,7, Maxime Barat, MD2, Olivier Glehen, MD, PhD4, Marc Pocard, MD, PhD5,7, Pascal Rousset, MD, PhD6, and Clarisse Eveno, MD, PhD5,7
Résultats d'une surveillance active dans la prise en charge des néoplasies appendiculaires mucineuses de bas grade (LAMN) rompues
Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, Dumont F, Brigand C, Passot G, Glehen O; RENAPE Network. BJS Open. 2018 Sep 27;3(2):195-202. doi: 10.1002/bjs5.97. eCollection 2019 Apr. PMID: 30957067
Free PMC article.
Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment.
Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ; PSOGI. Eur J Surg Oncol. 2021 Jan;47(1):11-35. doi: 10.1016/j.ejso.2020.02.012. Epub 2020 Feb 28. PMID: 32199769 Review.
Peritoneal pseudomyxoma after incomplete appendectomy.
Djelil D, Dohan A, Pocard M. Pleura Peritoneum. 2020 Aug 20;5(3):20200119. doi: 10.1515/pp-2020-0119. eCollection 2020 Sep. PMID: 33364339
Free PMC article.
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.
J Clin Oncol. 2012 Jul 10;30(20):2449-56.
When and When Not to Perform a Right Colon Resection with Mucinous Appendiceal Neoplasms.
Sugarbaker PH.
Ann Surg Oncol. 2017 Mar;24(3):729-732.
Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up.
Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R.
Ann Surg Oncol. 2017 Jan;24(1):187-193.
A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ; Peritoneal Surface Oncology Group International.
Am J Surg Pathol. 2016 Jan;40(1):14-26.
Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?
Delhorme JB, Elias D, Varatharajah S, Benhaim L, Dumont F, Honoré C, Goéré D.
Ann Surg Oncol. 2016 May;23(5):1618-24.
A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ, Semino-Mora C, Friedline CJ, Liu H, Bodi KL, McAvoy TJ, Francis J, Nieroda C, Sardi A, Dubois A, Lazinski DW, Camilli A, Testerman TL, Merrell DS.
Orphanet J Rare Dis. 2013 Jul 12;8:105.
Free PMC Article
Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL.
Orphanet J Rare Dis. 2014 May 5;9:71.
Free PMC Article
Depletion of mucin in mucin-producing human gastrointestinal carcinoma: Results from in vitro and in vivo studies with bromelain and N-acetylcysteine.
Amini A, Masoumi-Moghaddam S, Ehteda A, Liauw W, Morris DL.
Oncotarget. 2015 Oct 20;6(32):33329-44.
Free PMC Article
Pathophysiology and classification of pseudomyxoma peritonei.
Bignell M, Carr NJ, Mohamed F.
Pleura Peritoneum. 2016 Mar 1;1(1):3-13. doi: 10.1515/pp-2016-0008. Epub 2016 Apr 12. Review.
Free PMC Article
